The Current State of CRPC Management With Judd W. Moul, MD, FACS

In the past decade, much progress has been made in the management of castration-resistant prostate cancer (CRPC), with numerous new agents improving outcomes in patients with this disease. However, many challenges still remain. In this interview with i3 Health, Judd W. Moul, MD, FACS, Professor of Urologic Surgery at the Duke School of Medicine, discusses strategies that community oncologists and urologists can utilize to determine the best treatment for their patients. He also discusses the rol...
Continue reading

Educational Need in Castration-Resistant Prostate Cancer

Due to the increase in treatment options for castration-resistant prostate cancer (CRPC) in recent years, some confusion exists over the optimal therapeutic approach. A number of factors must be considered in CRPC treatment, including patient health status, rate of disease progression and disease burden, presence of bone or visceral metastases, mechanism of action and tolerability of available agents, and prior lines of therapy and response.Baseline data collected from i3 Health's continuing med...
Continue reading

Prostate Cancer: Adding Enzalutamide to First-Line Therapy

With around 170,000 men in the United States projected to be diagnosed with prostate cancer this year, it is the most common cancer in men. Androgen therapy is usually administered for progressive disease; however, hormone-sensitive prostate cancer can develop into castration-resistant prostate cancer, signifying treatment resistance to androgen deprivation therapy or to antiandrogens. There is a lack of understanding surrounding the transition from castration-sensitive to castration-resistant a...
Continue reading

Knowledge Gaps Surrounding CRPC Risk Assessment, Treatment

Over the past few years, the treatment options for castration-resistant prostate cancer (CRPC) have increased to include novel hormone therapies, second-generation taxanes, immunotherapy, and bone-targeted and bone metastasis-targeted agents. Due to an absence of large prospective trials, clinical decision making needs to be based on many different factors, including optimal treatment sequences and combinations, patient health status (eg, asymptomatic or symptomatic), rate of disease progression...
Continue reading

Treatment Selection Considerations in Castration-Resistant Prostate Cancer With Robert Dreicer, MD

Prostate cancer is the most common tumor type in men in the United States. Typically, androgen deprivation therapy (ADT) is administered for progressive disease. However, castration resistance or unresponsiveness to ADT or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Metastatic castration-resistant prostate cancer (CRPC) is the primary cause of prostate-re...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.